Eli Lilly (LLY) at 31 Times Forward Earnings: What $1,150 Assumes
Eli Lilly‘s second-quarter revenue was $23.0 billion, up 48% from a year earlier, and the quarter produced roughly $7.1 billion of net income. Few companies in any industry post that kind of number, and almost none do it while growing near 50%. The stock trades around $1,152.93 as I write this.
So the business is not the debate. The debate is what a buyer at this price has agreed to believe. At 38.7 times trailing earnings and about 30.8 times next year’s estimate, Lilly is priced for a long run of growth that does not stall, and the market has already been reminded once, in August 2025, what happens when a quarter disappoints: the shares fell 14.1% on the day.
My view is that Lilly is one of the best-run large companies in the market and that its stock is priced closer to fair than to cheap. I would own it as a measured position, not as the center of a portfolio, and I will show the arithmetic behind each half of that sentence.
What the last two years of revenue look like
The database shows annual revenue of $28.5 billion in 2022, $34.1 billion in 2023, $45.0 billion in 2024 and $65.2 billion in 2025. That is a company that more than doubled in three years. Net income went from $10.6 billion to $20.6 billion in the latest year, and operating margin reached 46%.
Quarterly numbers keep the same shape. Sales were about $19.8 billion in the first quarter of 2026 and $23.0 billion in the second, a 16% step up in one quarter, which puts the annualized run rate near $91.9 billion. Second-quarter GAAP net income was $7.1 billion against $5.7 billion a year earlier, up about 25%.
Look closer at that last comparison. Revenue grew 48% and net income grew 25%. GAAP net margin in the quarter was roughly 31%, against roughly 36% in the second quarter of 2025. I have not broken out which items pulled it down (acquired research charges and the cost of new plants both show up in reported profit), so I read it as a caution flag and not a verdict. A company growing this fast usually lets margin expand. Lilly’s did the opposite for one quarter, and the next report will show whether that was a blip.
Margins that most drugmakers cannot match
Gross margin was 83.0% last year, up from 81.3%. Research spending was $13.3 billion, roughly 20% of revenue, and it grew about 21%. That is the part I like most. A company spending a fifth of its sales on discovery while still keeping a 32% net margin is funding its next products out of current profit, and does not need the market’s permission.
It also explains why comparing Lilly with a conventional large pharmaceutical peer misleads. A slow-growth drug company can look cheap at a low multiple because its patents are expiring. Lilly is expensive because its patents, for now, are the opposite. The multiple is a bet on duration, and duration in pharma is limited by how many years remain before generics or newer drugs erode the franchise.
The two ways the multiple can be wrong
Consider what the forward estimate says. Analysts expect earnings per share of about $37.43 for the next fiscal year, against $29.79 over the last twelve months. That implies roughly 26% growth, and the forward multiple of 30.8 is simply the price divided by that estimate. The market is paying today for growth that has not been reported yet.
The five-year average P/E in the database is 67.5, which sounds like a reason to call today’s 38.7 cheap. I would not use it that way. Earnings were small in 2021 and 2022, so the ratio was inflated by a tiny denominator. Comparing today’s multiple with a period when profit was a fraction of its current size tells you about the past, not about value.
A more useful exercise is to hold the expected earnings fixed and vary the multiple. It is uncomfortable arithmetic, and it is why sizing matters.
| Multiple on $37.43 forward EPS | Implied share price | Versus about $1,153 today |
|---|---|---|
| 20 times | $749 | -35% |
| 25 times | $936 | -19% |
| 30.8 times (today) | $1,153 | 0% |
| 35 times | $1,310 | +14% |
The 25-times row is worth a pause. It is not an extreme scenario. It is where a slower-growing large pharmaceutical company with excellent margins could plausibly trade, and it lands within a rounding error of the lowest analyst target of $940. If growth stays above 40% and profit follows, the shares can hold today’s multiple. If growth decelerates toward the mid-teens, the multiple compresses and the price falls even while earnings keep rising. A stock can go down in a year when the company does everything right.
What analysts and the tape say
Twenty-one analysts cover the stock, 86% rate it a buy, and the average target of $1,373 sits about 19% above the price, with a range from $940 (about -18% from here) to $1,600. A range of that width is worth reading on its own. It says professionals who all like the company disagree by more than 70% on what the shares are worth.
The stock is 10.8% below its 52-week high of $1,293 and 63% above its low of $708. Short interest is only 0.8% of shares, so almost nobody is positioned for a collapse, which is a mixed signal. It means the crowd is comfortable. Comfortable crowds move sharply when the news surprises them.
Earnings days have been violent in both directions. The average move on report day has been 7.2%, the last one was +4.9%, and the worst of the five most recent was that 14.1% drop in 2025. The next report is scheduled for October 29, 2026. A holder who cannot stomach a 10% move in a day on a single report is holding too much.
Insurers, employers and the price of a shot
Lilly’s drugs treat conditions that hundreds of millions of people have, which is the source of the growth and the source of the political risk. The buyers that matter are insurers, employers and government programs, and every one of them is looking at the same bill. I wrote about how a large insurer’s cost pressure shows up in its own numbers in the UnitedHealth medical cost ratio post, and that is the mirror image of this story: what looks like revenue to Lilly looks like cost to the payer.
That is why the price a company realizes per prescription matters as much as the volume. A business can grow 40% in units and only 25% in revenue if net prices fall. Lower prices to widen access can be good business, but I would want each quarter to show volume rising faster than price is falling. I could not verify the exact product-level split this week, so I am not putting numbers on it here, and I would read the company’s own release before making any decision that depends on it.
Supply, competition and the pipeline
Supply was tight for these drugs for a long stretch, and the company is spending heavily on new manufacturing. New plants take years to build and cost billions, much like semiconductor fabs. When capacity is short, demand hides mistakes. When capacity catches up, the market finds out how much of the demand was patient need and how much was people waiting in line.
Competition is the second risk. Novo Nordisk sells the other well-known obesity and diabetes drugs, and several large companies are developing rivals. Lilly’s own next products, including an oral candidate and a next-generation injectable, are in development, and I would treat any timing as something to confirm on the company’s pipeline page. A pill would widen the market to people who dislike injections. It would also invite price competition, and a large market does not stay a duopoly forever.
There is a concentration angle too. Two brands carry most of the growth. If a safety finding surfaced for a treatment taken by millions of people, the shares would fall before the science was settled.
How much I would hold
A high-quality company at a fair price and a volatile earnings pattern points to a moderate position size. I laid out the reasoning behind sizing by volatility in another post, and the same logic applies here: the danger here is the one-day gap on a report, more than a slow drift. Compared with a steadier large-cap that trades near 27.5 times earnings, Lilly asks the buyer to accept more event risk for a growth rate that is roughly double.
What would prove me wrong on the cautious side? Two consecutive quarters where revenue growth stays above 40% and GAAP margin climbs back above the mid-30s. That would tell me the earnings estimate is too low and the 31 times is closer to 25 times on real profit.
What would prove me wrong on the enthusiastic side? Net price per prescription falling faster than volume rises for two quarters in a row. Then the growth rate of the next few years is smaller than the market has paid for.
The October 29 report is the first test. Second-quarter revenue of $23.0 billion sets the bar: if the third quarter does not exceed it by at least 5%, I would consider the forward multiple too rich for a full position.
Analysis and opinion only, not investment advice. Figures come from Lilly’s filings on SEC EDGAR and its annual reports, plus a market database for prices, estimates and analyst targets; valuation multiples are approximate and were checked on September 22, 2026.